Drug Profile
Research programme: phosphotransferase inhibitors - Ignyta
Alternative Names: RXDX-102; RXDX-103; RXDX-104Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Nerviano Medical Sciences
- Developer Ignyta
- Class
- Mechanism of Action CDC7 protein kinase inhibitors; Proto oncogene protein c ret inhibitors; TrkA receptor antagonists; TrkB receptor antagonists; TrkC receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Cancer in USA
- 14 Mar 2016 Ignyta has patent protection for RXDX 103 in USA (Ignyta 10-K, March 2016)
- 26 Feb 2016 Ignyta discontinues development RXDX 103 in USA for Cancer (Ignyta 10-K, March 2016)